Advancing 89 Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential.

MLA

Wuensche, Thomas E., et al. “Advancing 89 Zr-Immuno-PET in Neuroscience with a Bispecific Anti-Amyloid-Beta Monoclonal Antibody - The Choice of Chelator Is Essential.” Theranostics, vol. 12, no. 16, Oct. 2022, pp. 7067–79. EBSCOhost, https://doi.org/10.7150/thno.73509.

APA

Wuensche, T. E., Stergiou, N., Mes, I., Verlaan, M., Schreurs, M., Kooijman, E. J. M., Janssen, B., Windhorst, A. D., Jensen, A., Asuni, A. A., Bang-Andersen, B., Beaino, W., Dongen, G. A. M. S., & Vugts, D. J. (2022). Advancing 89 Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential. Theranostics, 12(16), 7067–7079. https://doi.org/10.7150/thno.73509

Chicago

Wuensche, Thomas E, Natascha Stergiou, Iris Mes, Mariska Verlaan, Maxime Schreurs, Esther J M Kooijman, Bart Janssen, et al. 2022. “Advancing 89 Zr-Immuno-PET in Neuroscience with a Bispecific Anti-Amyloid-Beta Monoclonal Antibody - The Choice of Chelator Is Essential.” Theranostics 12 (16): 7067–79. doi:10.7150/thno.73509.